Smith & Nephew maintains full-year guidance despite mixed Q1

Smith & Nephew’s Q1 sales were mixed, but the company remains confident in its full-year forecast.

Smith & Nephew (LSE: SN) shares rose 2.5% after the medical technology company reported in-line first-quarter sales despite weakness in its Advanced Wound Management unit.

Overall sales rose 2.9% on an underlying basis to $1.39 billion, with growth in Orthopaedics and Sports Medicine & ENT offsetting a 2.0% decline in Advanced Wound Management.

Orthopaedics revenue rose 4.4%, driven by strong growth outside the US. Sports Medicine & ENT revenue rose 5.5%, supported by recent product launches.

The company reiterated its full-year outlook for 5.0% to 6.0% underlying revenue growth and a trading profit margin of at least 18.0%.

CEO Deepak Nath said: “We are confident in our outlook and look forward to all three of our business units contributing as we deliver another year of strong revenue growth.”

Subscribe to Investomania for more Smith & Nephew news and updates.

Sign up for Investomania

Subscribe to the Investomania newsletter to have our daily recap delivered directly to your inbox.

No spam. Unsubscribe anytime.